Intervertebral disc degeneration adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,113 adverse event reports that record the MedDRA preferred term Intervertebral disc degeneration. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 234 reports in the 12 months to June 2026 and 327 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 120 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Intervertebral disc degeneration name as a suspect product, in order of name
Drug	Class	Reports with this term
Accutane	Retinoid	36
Actemra	Interleukin-6 receptor antagonist	112
Actonel	Bisphosphonate	71
Albuterol	beta2-Adrenergic agonist	65
Albuterol sulfate	beta2-Adrenergic agonist	32
Alendronate sodium	Bisphosphonate	411
Alendronate Sodium Cholecalciferol		57
Allopurinol	Xanthine oxidase inhibitor	82
Ampyra	Potassium channel blocker	29
Apixaban	Factor Xa inhibitor	75
Arava	Antirheumatic agent	37
Aredia		240
Aspirin	Nonsteroidal anti-inflammatory drug	67
Atripla		149
Aubagio	Pyrimidine synthesis inhibitor	28
Avonex	Interferon beta	225
Bisoprolol	beta-Adrenergic blocker	53
Bisoprolol fumarate	beta-Adrenergic blocker	40
Boniva		93
Breo Ellipta	Corticosteroid	64
Celebrex	Nonsteroidal anti-inflammatory drug	71
Cholecalciferol		36
Complera	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	68
Cosentyx	Interleukin-17A antagonist	143
Crestor	HMG-CoA reductase inhibitor	34
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	70
Diclofenac	Nonsteroidal anti-inflammatory drug	49
Digoxin	Cardiac glycoside	42
Dilaudid	Opioid agonist	68
Dupixent	Interleukin-4 receptor alpha antagonist	40
Duragesic		26
Duragesic-100		40
Eliquis	Factor Xa inhibitor	39
Enbrel	Tumor necrosis factor blocker	505
Erelzi		50
Ergocalciferol	Provitamin D2 compound	52
Fentanyl	Opioid agonist	36
Finasteride	5-alpha reductase inhibitor	83
Folic acid		40
Formoterol Fumarate Mometasone Furoate		47
Forteo	Parathyroid hormone analog	96
Fosamax	Bisphosphonate	957
Fosamax Plus D		212
Furosemide	Loop diuretic	85
Gabapentin	Anti-epileptic agent	142
Gilenya	Sphingosine 1-phosphate receptor modulator	63
Humalog	Insulin analog	40
Human immunoglobulin g	Human immunoglobulin G	25
Humira		970
Hydrocodone bitartrate and acetaminophen	Opioid agonist	70
Hydroxychloroquine	Antimalarial	25
Ibuprofen	Nonsteroidal anti-inflammatory drug	40
Infliximab	Tumor necrosis factor blocker	28
Januvia	Dipeptidyl peptidase 4 inhibitor	37
Leflunomide	Antirheumatic agent	101
Lipitor	HMG-CoA reductase inhibitor	58
Lisinopril	Angiotensin converting enzyme inhibitor	28
Lyrica		233
Metformin	Biguanide	27
Methotrexate	Folate analog metabolic inhibitor	251
Methotrexate sodium	Folate analog metabolic inhibitor	71
Metoclopramide	Dopamine-2 receptor antagonist	25
Montelukast sodium	Leukotriene receptor antagonist	55
Morphine	Opioid agonist	28
Morphine sulfate	Opioid agonist	63
MS Contin	Opioid agonist	38
Naproxen	Nonsteroidal anti-inflammatory drug	26
Neurontin		32
Nexium	Proton pump inhibitor	285
Ocrevus	CD20-directed cytolytic antibody	47
Olmesartan		48
Olmesartan medoxomil	Angiotensin 2 receptor blocker	44
Omeprazole	Proton pump inhibitor	38
Orencia	Selective T cell costimulation modulator	73
Otezla	Phosphodiesterase 4 inhibitor	33
Oxycodone	Opioid agonist	27
Oxycodone and acetaminophen	Opioid agonist	58
Oxycodone hydrochloride	Opioid agonist	143
OxyContin	Opioid agonist	137
Oxymorphone hydrochloride	Opioid agonist	27
Pantoprazole	Proton pump inhibitor	114
Percocet	Opioid agonist	39
Plaquenil	Antimalarial	34
Prednisone	Corticosteroid	210
Pregabalin		25
Prilosec	Proton pump inhibitor	70
Prilosec OTC	Proton pump inhibitor	36
Prolia	RANK ligand inhibitor	100
Promethazine hydrochloride and codeine phosphate	Opioid agonist	27
Propecia	5-alpha reductase inhibitor	49
Propoxyphene Hydrochloride		27
Rebif	Interferon beta	77
Remicade	Tumor necrosis factor blocker	96
Revlimid	Thalidomide analog	66
Rinvoq	Janus kinase inhibitor	153
Rituxan	CD20-directed cytolytic antibody	58
Rituximab	CD20-directed cytolytic antibody	142
Seroquel	Atypical antipsychotic	67
Singulair	Leukotriene receptor antagonist	50
Skyrizi	Interleukin-23 antagonist	65
Stribild	Cytochrome P450 3A inhibitor	88
Sulfasalazine	Aminosalicylate	47
Symbicort	Corticosteroid	34
Tamsulosin hydrochloride	alpha-Adrenergic blocker	62
Tecfidera		56
Theophylline	Methylxanthine	69
Tiotropium bromide	Anticholinergic	99
Tramadol		41
Tramadol hydrochloride	Opioid agonist	34
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	223
Tysabri	Integrin receptor antagonist	173
Umeclidinium bromide		78
Valsartan	Angiotensin 2 receptor blocker	28
Vicodin		28
Vioxx		222
Viread	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	122
Xeljanz	Janus kinase inhibitor	145
Xyrem	Central nervous system depressant	192
Zenhale		33
Zometa		364

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 46 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Intervertebral disc degeneration name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	139
alpha-Adrenergic blocker	81
Angiotensin 2 receptor blocker	144
Anti-epileptic agent	162
Anticholinergic	101
Antimalarial	72
Antirheumatic agent	138
Atypical antipsychotic	109
Benzodiazepine	66
beta-Adrenergic blocker	124
beta2-Adrenergic agonist	108
Bisphosphonate	1,492
CD20-directed cytolytic antibody	263
Central nervous system depressant	215
Corticosteroid	402
Cytochrome P450 3A inhibitor	88
Factor Xa inhibitor	126
Folate analog metabolic inhibitor	322
GLP-1 receptor agonist	57
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	130
HMG-CoA reductase inhibitor	142
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	293
Insulin analog	87
Integrin receptor antagonist	202
Interferon beta	305
Interleukin-17A antagonist	149
Interleukin-23 antagonist	67
Interleukin-6 receptor antagonist	114
Janus kinase inhibitor	326
Kinase inhibitor	130
Leukotriene receptor antagonist	111
Loop diuretic	87
Methylxanthine	69
Nonsteroidal anti-inflammatory drug	313
Opioid agonist	889
Parathyroid hormone analog	99
Proton pump inhibitor	597
Provitamin D2 compound	59
RANK ligand inhibitor	118
Selective T cell costimulation modulator	89
Serotonin and norepinephrine reuptake inhibitor	113
Serotonin reuptake inhibitor	50
Sphingosine 1-phosphate receptor modulator	71
Thalidomide analog	73
Tumor necrosis factor blocker	723
Xanthine oxidase inhibitor	82

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Intervertebral disc degeneration, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Intervertebral disc degeneration
Age	Reports	Share
Under 2	1	under 0.1%
2 to 11	3	under 0.1%
12 to 17	13	0.1%
18 to 44	769	8.4%
45 to 64	2,857	31.4%
65 to 74	1,114	12.2%
75 and over	608	6.7%
Age not given	3,748	41.1%

Sex of the patient in the reports that record Intervertebral disc degeneration
Sex	Reports	Share
Female	5,954	65.3%
Male	2,652	29.1%
Unknown or not given	507	5.6%

Age and sex are as the report gives them. 81.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Intervertebral disc degeneration: adverse event reports that record this term. https://reportedreactions.com/reaction/intervertebral-disc-degeneration/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Intervertebral disc degeneration mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page